The short answer
The most commonly reported adverse effects of orforglipron are gastrointestinal: nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain. This profile is characteristic of GLP-1 receptor agonism generally rather than specific to orforglipron, and follows directly from how the receptor affects gastric emptying and satiety signalling.
Key facts
- Most common effects
- Nausea, constipation, diarrhoea, vomiting
- Also reported
- Dyspepsia, abdominal pain
- Nature
- Class effect across GLP-1 agonists
- Mechanistic cause
- Delayed gastric emptying, area postrema signalling
- Typical pattern
- Dose-related, most pronounced during escalation
- Reporting route (UK)
- MHRA Yellow Card scheme
Why the effects are gastrointestinal
GLP-1 receptor agonism slows gastric emptying and acts on brainstem structures including the area postrema, which is central to both satiety and nausea. The therapeutic effect and the principal adverse effect therefore arise from the same mechanism rather than from an off-target action. This is why the profile is so consistent across the class regardless of chemistry. Peptide or not, injected or oral.
How this compares across the class
Gastrointestinal events dominate for every incretin compound reported to date. In retatrutide's TRIUMPH-1, nausea was reported by 42.4% on the 12 mg arm against 14.8% on placebo, and diarrhoea by 32.0% against 13.5%. Multi-agonists engaging more receptors generally report higher rates than GLP-1-only compounds, which is one of the trade-offs that comes with larger effect size.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Discontinuation is the figure that matters
Incidence of an adverse event says less than how many people stopped because of one. TRIUMPH-1 reported 11.3% discontinuation due to adverse events on 12 mg against 4.9% on placebo. That number is frequently absent from summaries, and it is the one that connects tolerability to real-world outcome. A compound nobody can stay on does not deliver its trial result.
What the tablet format does and does not change
Being a tablet with no absorption enhancer removes the dosing conditions oral semaglutide carries, and removes injection-site reactions entirely. It does not change the gastrointestinal profile, because that follows from receptor pharmacology rather than route. A more convenient tablet is not automatically a better-tolerated drug.
Reporting suspected adverse effects in the UK
The MHRA operates the Yellow Card scheme for reporting suspected adverse drug reactions, defective medicines and falsified products. Reports can be submitted by healthcare professionals and by patients directly. It is also the correct route for reporting a suspected counterfeit GLP-1 product.
Frequently asked questions
Are orforglipron's side effects different because it is a tablet?
No. The gastrointestinal profile follows from GLP-1 receptor pharmacology, not from route. The tablet removes dosing conditions and injection-site reactions, not nausea.
Why do multi-agonists report higher rates?
Engaging more receptors increases both the therapeutic effect and the mechanism-linked adverse effects. Larger effect sizes have consistently come with higher gastrointestinal burden.
How do I report a side effect in the UK?
Through the MHRA Yellow Card scheme, which accepts reports from healthcare professionals and from patients directly.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- How NICE Decides Whether the NHS Funds a MedicineLicensing and funding are separate decisions. How NICE appraisal works, why obesity medicines are difficult cases, and what is expected on 18 November 2026.
- CagriSema FDA Filing: Where the Review StandsNovo Nordisk filed CagriSema with the FDA in December 2025 on the REDEFINE programme. A decision is expected in Q4 2026. What the trials reported.
- TRIUMPH-5: The Retatrutide vs Tirzepatide Head-to-HeadTRIUMPH-5 randomises 800 adults to retatrutide or tirzepatide over Phase 3. Primary completion is November 2026 - the first direct comparison of the two.
- TRIUMPH-6: Maintenance of Weight ReductionTRIUMPH-6 tests whether reduction is sustained on maintenance dosing. 643 participants, primary completion April 2028 - the field's key question is years away.
- Retatrutide Expanded Access: What It Actually IsA pre-approval expanded access record for retatrutide is listed as available. What expanded access means, who it is for, and what it is emphatically not.